Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Antimicrobial Development in the Era of Emerging Resistance

Author(s): Antonio Sorlozano, Cristina Carrasco, Jose Cabeza, Enrique Villegas and Jose Gutierrez

Volume 9 , Issue 8 , 2009

Page: [938 - 955] Pages: 18

DOI: 10.2174/138955709788681564

Price: $65

Abstract

Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). Moreover, all of them would be useful for skin and soft tissue infections.

Keywords: Faropenem, dalbavancin, telavancin, oritavancin, ceftobiprole, iclaprim


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy